| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
6,130,000 |
| Market
Cap: |
1.71(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2787 - $0.2787 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing products that address unmet medical needs in the treatment of cardiopulmonary diseases. Co.'s focus is the continued development of its nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using its proprietary pulsatile nitric oxide delivery platform, INOpulse. Co.'s INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide. Co. is developing its INOpulse for the treatment of patients with fibrotic interstitial lung disease at a risk for pulmonary hypertension.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
1,211,262 |
1,780,717 |
| Total Sell Value |
$0 |
$0 |
$223,345 |
$5,615,495 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
2 |
4 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shah Parag Suresh |
VP Proj Mgmt & Distribution |
• – – |
2018-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
20,690 |
60,238 |
|
- |
|
| Quinn Deborah |
Chief Medical Officer |
• – – |
2018-01-04 |
4 |
D |
$2.49 |
$82,454 |
D/D |
(33,114) |
75,054 |
|
- |
|
| Shah Parag Suresh |
VP Proj Mgmt & Distribution |
• – – |
2018-01-04 |
4 |
D |
$2.49 |
$57,718 |
D/D |
(23,180) |
39,548 |
|
- |
|
| Fernandes Peter |
Chief Regulatory & Safety Offr |
• – – |
2018-01-04 |
4 |
D |
$2.49 |
$87,949 |
D/D |
(35,321) |
82,453 |
|
- |
|
| Dekker Martin |
VP of Engineering & Manuf |
• – – |
2018-01-04 |
4 |
D |
$2.49 |
$60,467 |
D/D |
(24,284) |
55,308 |
|
- |
|
| Schoeps Megan |
Principal Financial Officer |
• – – |
2017-12-13 |
4 |
OE |
$0.49 |
$490 |
D/D |
1,000 |
19,248 |
|
- |
|
| Amin Naseem |
Director |
– • – |
2017-09-29 |
4 |
B |
$0.00 |
$0 |
D/D |
456,432 |
1,230,314 |
2.31 |
- |
|
| Peacock Jonathan M |
Director |
– • – |
2017-09-29 |
4 |
B |
$0.00 |
$0 |
D/D |
248,962 |
815,351 |
2.31 |
- |
|
| Luehring Jens |
Director |
– • • |
2017-09-29 |
4 |
B |
$0.00 |
$0 |
D/D |
10,000 |
80,658 |
3.84 |
- |
|
| Amin Naseem |
Director |
– • – |
2017-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
36,232 |
773,882 |
|
- |
|
| Weinstein Adam |
Director |
– • • |
2017-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
25,363 |
42,130 |
|
- |
|
| Luehring Jens |
Director |
– • • |
2017-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,798 |
70,658 |
|
- |
|
| Peacock Jonathan M |
Director |
– • – |
2017-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
57,972 |
566,389 |
|
- |
|
| Tasse Daniel |
Director |
– • – |
2017-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
25,363 |
170,617 |
|
- |
|
| Moura Andre V. |
Director |
– • – |
2017-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
32,609 |
53,325 |
|
- |
|
| Schoeps Megan |
Principal Financial Officer |
• – – |
2017-05-17 |
4 |
D |
$1.40 |
$14,683 |
D/D |
(10,459) |
18,248 |
|
- |
|
| Edmonds Amy |
VP Clinical Operations & Admin |
• – – |
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
56,411 |
79,624 |
|
- |
|
| Fernandes Peter |
Chief Regulatory & Safety Offr |
• – – |
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
82,052 |
117,774 |
|
- |
|
| Schoeps Megan |
Principal Financial Officer |
• – – |
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
24,039 |
28,707 |
|
- |
|
| Quinn Deborah |
Chief Medical Officer |
• – – |
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
76,924 |
108,168 |
|
- |
|
| Shah Parag Suresh |
VP Proj Mgmt & Distribution |
• – – |
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
53,847 |
62,728 |
|
- |
|
| Dekker Martin |
VP of Engineering & Manuf |
• – – |
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
56,411 |
79,592 |
|
- |
|
| Tenenbaum Fabian |
Chief Executive Officer |
• – – |
2017-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
120,193 |
263,050 |
|
- |
|
| Schoeps Megan |
Principal Financial OfficerOff |
• – – |
2017-03-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,668 |
|
- |
|
| Luehring Jens |
Director |
– • • |
2016-12-09 |
4 |
B |
$0.56 |
$11,200 |
D/D |
20,000 |
39,860 |
3.92 |
- |
|
188 Records found
|
|
Page 5 of 8 |
|
|
